JNJ vs ABBV: Johnson & Johnson vs AbbVie Inc.
Side-by-side snapshot of two Healthcare companies — key metrics from our latest data. Reference only, not investment advice.
| Metric | JNJ | ABBV |
|---|---|---|
| Company | Johnson & Johnson | AbbVie Inc. |
| Price | $253.04 | $254.49 |
| Market Cap | $609.12B | $449.63B |
| P/E Ratio | 29.32 | 124.75 |
| EPS | $8.63 | $2.04 |
| Dividend Yield | 2.12% | 2.72% |
| 52-Week High | $269.43 | $261.64 |
| 52-Week Low | $162.78 | $184.63 |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYQ | NYQ |
| Employees | 138,200 | 57,000 |
Johnson & Johnson and AbbVie Inc. both operate in the Healthcare sector. JNJ trades at a market cap of $609.12B against ABBV's $449.63B. Valuation-wise, JNJ carries a trailing P/E of 29.32 versus 124.75 for ABBV. How these figures compare depends on each company's growth profile, margins and outlook — the snapshot above is a starting point for further research, not a recommendation.
Figures are from our latest data snapshot and may not reflect current market prices. See the full profiles: Johnson & Johnson and AbbVie Inc.. This is not financial advice.
Recommended Reading & Tools
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Philip Fisher's growth-investing classic on evaluating management and moats.
Check Price →A desk whiteboard for tracking tickers, levels and ideas at a glance.
Check Price →Roger Lowenstein's definitive biography of the world's most famous investor.
Check Price →Data snapshot: 18 July 2026 (Yahoo Finance) · Page last built: